ProgenityLogo.jpg
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
June 02, 2021 07:00 ET | Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
ProgenityLogo.jpg
Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death
May 04, 2021 07:30 ET | Progenity, Inc.
Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially...
22157.jpg
Global Human Gene Sequencing Market Report 2021: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
April 26, 2021 05:28 ET | Research and Markets
Dublin, April 26, 2021 (GLOBE NEWSWIRE) -- The "Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to...
ProgenityLogo.jpg
Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
April 08, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies
April 06, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
March 18, 2021 16:05 ET | Progenity, Inc.
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M...
ProgenityLogo.jpg
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
March 12, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity Announces $25 Million Private Placement
February 23, 2021 07:45 ET | Progenity, Inc.
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
ProgenityLogo.jpg
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
February 17, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
ProgenityLogo.jpg
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
February 12, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...